Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385549 | 0.82 | ALOX5AP (0.43) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL4385547 | 0.82 | ALOX5AP (0.43) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL7554164 | 0.81 | DRD2 (0.53) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL30681441 | 0.81 | DRD2 (0.53) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL4289075 | 0.81 | DRD2 (0.53) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL7993369 | 0.80 | DRD2 (0.54) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL4436739 | 0.78 | NOTUM (0.43) | NOTUMACE | |
| SCHEMBL20505468 | 0.77 | LMNA (0.46) | NOTUMNPC1ALDH1A1 | |
| SCHEMBL30681525 | 0.77 | NOTUM (0.48) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL30681248 | 0.75 | DRD2 (0.45) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | NOTUM 1979/4885NPC1 4088/4885ALDH1A1 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.